62 results on '"Ariga, Takuro"'
Search Results
52. Predictive factors of uterine movement during definitive radiotherapy for cervical cancer.
- Author
-
Maemoto, Hitoshi, Toita, Takafumi, Ariga, Takuro, Heianna, Joichi, Yamashiro, Tsuneo, and Murayama, Sadayuki
- Abstract
To determine the predictive factors affecting uterine movement during radiotherapy (RT), we quantified interfraction uterine movement using computed tomography (CT) and cone-beam CT (CBCT). A total of 38 patients who underwent definitive RT for cervical cancer were retrospectively analyzed. We compared pre-RT planning CT (n = 38) and intratreatment CBCT (n = 315), measuring cervical and corporal movement in each direction. Correlations between uterine movement and volume changes of the bladder and rectum on all CBCT scans were analyzed using Spearman rank correlation analysis. Relationships between the mean uterine movement and patient factors were analyzed using the Mann-Whitney test. The mean corpus movement was: superior margin (cranio-caudal direction), 7.6 ± 5.9 mm; anterior margin (anteroposterior direction), 8.3 ± 6.3 mm; left margin (lateral direction), 3.3 ± 2.9 mm; and right margin (lateral direction), 3.0 ± 2.3 mm. Generally, the mean values for cervical movement were smaller than those for the corpus. There was a significant, weak correlation between changes in bladder volume and the movement of the superior margin of the corpus (ρ = 0.364, P < 0.001). There was a significant difference in movement of the superior margin of the corpus between the subgroups with and without a history of previous pelvic surgery (P = 0.007). In conclusion, change in bladder volume and a history of previous surgery were significantly related to intrafractional corpus movement; however, our observations suggest that the accurate prediction of uterine movement remains challenging.
- Published
- 2017
- Full Text
- View/download PDF
53. 限局性前立腺癌に対する I-125 密封小線源療法150例の検討
- Author
-
Miyazato, Minoru, Ariga, Takuro, Maemoto, Hitoshi, Kusada, Takeaki, Ashikari, Asuka, Uema, Namiko, Miyagi, Ryota, Nakanishi, Shotaro, Goya, Masato, Murayama, Sadayuki, and Saito, Seiichi
- Subjects
brachytherapy ,iodine-125 ,prostate cancer - Abstract
Background: We retrospectively evaluated the outcome of brachytherapy with permanent iodine-125 seed implantation for prostate cancer. Methods: From 2009 to2016, 150 patients(49 in low risk, 81 intermediate, 20 high),mean age 67.1 y, which were performed brachytherapy in our hospital were enrolled in this study. Results: The average prostate volume was 27.4cc, mean International Prostate Symptom Score 9 in these patients. In postplan evaluation, mean prostate V100 93.8%, D90 in brachytherapy alone 173.9Gy, combined with external beam radiation 116.8Gy, rectum V100 in brachytherapy alone 0.27cc, combined with external beam radiation 0.13cc, urethraD90 in brachytherapy alone 89.9Gy, combined with external beam radiation 64.4Gy. The biochemical progression-free survival in 5 years was 97.0% in low risk, while 96.3% in intermediate and no patients in high risk demonstrated PSA relapse during the observation. Migration of seeds was occurred in 3.3%. Adverse event was urinary retention in 2, hematuria in 2, proctitis in 2, rectal bleeding in 2, more than grade 3 was noted in only one patient. Conclusions: The outcome of brachytherapy in our hospital was safe and feasible with low side effects., 論文
54. Therapeutic efficacy of selective intraarterial chemoradiotherapy with docetaxel and nedaplatin for human papilloma virus-negative oropharyngeal cancer.
- Author
-
Heianna, Joichi, Makino, Wataru, Hirakawa, Hitoshi, Agena, Shinya, Tomita, Hayato, Ariga, Takuro, Ishikawa, Kazuki, Takehara, Shota, Kusada, Takeaki, Maemoto, Hitoshi, Maeda, Hiroyuki, and Murayama, Sadayuki
- Subjects
- *
OROPHARYNGEAL cancer , *TREATMENT effectiveness , *CONE beam computed tomography , *DOCETAXEL , *PAPILLOMA , *RADIATION injuries , *CASTRATION-resistant prostate cancer , *THERAPEUTIC use of antineoplastic agents , *PAPILLOMAVIRUSES , *RETROSPECTIVE studies , *ORGANOPLATINUM compounds , *CISPLATIN - Abstract
Objective: Human papilloma virus-negative oropharyngeal cancer has not achieved satisfactory outcomes compared with those of human papilloma virus-positive oropharyngeal cancer. This study evaluated the therapeutic efficacy of selective intraarterial chemoradiotherapy with the docetaxel and nedaplatin regimen for human papilloma virus-negative oropharyngeal cancer.Methods: Twenty-two consecutive patients with human papilloma virus-negative oropharyngeal cancer who had undergone selective intraarterial chemoradiotherapy were retrospectively analyzed. The primary tumor and whole neck were irradiated (50 Gy). Subsequently, the primary site and metastatic lymph nodes were boosted by 20 Gy. The intraarterial chemotherapy regimen comprised a combination of nedaplatin (80 mg/m2) and docetaxel (60 mg/m2), which was initially administered at the start of radiotherapy and was given every 4 weeks for three sessions. Each intraarterial dose of an anticancer agent was determined according to the percentage of the tumor volume supplied by the target artery to the total tumor volume, which was intraoperatively measured via cone-beam computed tomography. The outcome measures were locoregional control, disease-free survival, and overall survival rates and adverse events. Statistical analyses were performed using the Kaplan-Meier method.Results: The median follow-up period was 59 (range, 15-103) months. The T stage was T1/T2 in 5 patients (23%), T3 in 5 patients (23%), and T4 in 12 patients (54%). Cervical lymph node metastasis was staged as ≥N2c in 7 (32%) patients. Complete response was achieved in all patients at the first imaging examination after intraarterial chemoradiotherapy. The 5-year locoregional control, disease-free survival, and overall survival rates were 96% (95% confidence interval, 0.72-0.99), 91% (95% confidence interval, 0.68-0.98), and 100% (95% confidence interval, not available), respectively. Regarding serious acute adverse events, grade 4 laryngeal edema and leukopenia were observed in 1 (5%) and 11 patients (50%), respectively. No other serious acute adverse events were observed.Conclusion: Selective intraarterial chemoradiotherapy with docetaxel and nedaplatin has the potential to achieve favorable locoregional control, disease-free survival, and overall survival rates in human papilloma virus-negative oropharyngeal cancer. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
55. A potential usefulness of ultra-high-resolution computed tomography in quality assurance of remote after-loading system for cervical cancer.
- Author
-
Kinjyo M, Nishie A, Kudaka R, Nakano S, and Ariga T
- Abstract
Intracavitary brachytherapy with a remote after-loading system (RALS) is performed as a part of radical radiation therapy in cervical cancer. The radiation source is delivered directly through an applicator placed inside the uterus or vagina. Thorough quality control is important to prevent accidents that can lead to serious irradiation error, and an applicator check is one such quality control measure. We experienced a clinical situation in which a small volume of water was observed in the lumen of a post-sterilized applicator on treatment-planning CT. Although the submersion test was negative and no air bubbles emerged from the applicator, ultra-high-resolution computed tomography (U-HRCT) showed a linear crack reaching the inside of the applicator. This abnormality was not identified on treatment-planning CT, which has lower spatial resolution than U-HRCT. In addition, no linear cracks were seen on U-HRCT images of eight other applicators considered to be free from damage. U-HRCT may have superior potential to detect applicator damage and could be useful for quality assurance of the RALS procedure., (© The Author(s) 2024. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
56. Prognostic Factors and Treatment Outcome for Patients with Stage IVB Cervical Cancer.
- Author
-
Oishi S, Kudaka W, Toita T, Ariga T, Nakamoto T, Wakayama A, Nagai Y, Kaneshima I, Nishihira K, and Aoki Y
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell therapy, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms mortality, Lung Neoplasms therapy, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms therapy, Carcinoma, Squamous Cell secondary, Lung Neoplasms secondary, Uterine Cervical Neoplasms pathology
- Abstract
Aim: We report a retrospective evaluation for patients with stage IVB cervical cancer in order to identify survival rates and to improve our current practice., Patients and Methods: We analyzed 85 patients with stage IVB cervical cancer. For patients appropriate for radical treatment, a combination of external-beam radiotherapy and intracavitary brachytherapy was delivered with/without chemotherapy. Patients with distant metastasis were treated using systemic chemotherapy or palliative radiotherapy., Results: Forty-two patients were treated using radiotherapy alone, 31 using chemotherapy followed by radiotherapy, eight using chemotherapy alone, and four using best supportive care. The 5-year overall survival rate was 9.9%. Multivariate analysis revealed leukocytosis and a poor performance status were independent prognostic factors. Of the 43 patients without these prognostic factors, patients with only lymph node metastasis had a 5-year overall survival rate of 40.5%., Conclusion: Radical treatment should be considered in patients who have only lymph rode metastasis and are without leukocytosis and a poor performance status., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2016
57. [Current Status and Perspective of Chemoradiotherapy for Uterine Cervical Cancer].
- Author
-
Toita T, Ariga T, Kasuya G, Hashimoto S, Maemoto H, Heianna J, Kakinohana Y, and Murayama S
- Subjects
- Female, Humans, Lymphatic Metastasis, Molecular Targeted Therapy, Radiotherapy Dosage, Radiotherapy, Intensity-Modulated, Uterine Cervical Neoplasms pathology, Chemoradiotherapy adverse effects, Uterine Cervical Neoplasms therapy
- Abstract
Fifteen years has passed since the NCI announced the clinical importance of concurrent chemoradiotherapy (CCRT) in radiotherapy for patients with locoregionally advanced uterine cervical cancer. Numerous clinical trials have been performed to further improve the outcomes of CCRT. In addition to investigations of chemotherapeutic regimens and schedules, adaptation of novel radiotherapy methods such as image-guided brachytherapy (IGBT) and intensity-modulated radiotherapy (IMRT) is encouraged in CCRT for cervical cancer.
- Published
- 2015
58. Concurrent chemoradiotherapy for non-bulky stage IB/II cervical cancer without pelvic node enlargement.
- Author
-
Wakayama A, Inamine M, Kudaka W, Nagai Y, Nakamoto T, Ooyama T, Ariga T, Kasuya G, Toita T, and Aoki Y
- Subjects
- Adenocarcinoma pathology, Adult, Aged, Carcinoma, Squamous Cell pathology, Chemoradiotherapy, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Recurrence, Local therapy, Neoplasm Staging, Prognosis, Retrospective Studies, Uterine Cervical Neoplasms pathology, Adenocarcinoma therapy, Carcinoma, Squamous Cell therapy, Neoplasm Recurrence, Local diagnosis, Pelvis pathology, Uterine Cervical Neoplasms therapy
- Abstract
Background: Concurrent chemoradiotherapy (CCRT) has not been extensively studied in patients with small cervical cancer tumors with no pelvic node enlargement., Patients and Methods: We retrospectively analyzed 55 patients with stage IB1-IIB cervical cancer and tumors of ≤40 mm with no pelvic node enlargement treated with radiotherapy (RT)-alone., Results: Cancer recurred in seven patients. Patient age (≤63 years) was identified as an independent factor for better disease-free survival (DFS) (p=0.027), and tumor size (≥25 mm) had a tendency to correlate with reduced locoregional DFS (p=0.089) by the Cox hazard model. Among patients aged 63 years or less, cancer recurred in five out of 18 patients with tumors of ≥25 mm, but in only one of 10 patients with tumors of ≤24 mm., Conclusion: In patients with stage IB1-IIB cervical cancer and small tumors with no node enlargement, CCRT may provide a better disease control for the group aged 63 years or less and with tumor size of 25 mm or more.
- Published
- 2013
59. Postoperative radiotherapy for uterine cervical cancer: impact of lymph node and histological type on survival.
- Author
-
Kasuya G, Ogawa K, Iraha S, Nagai Y, Hirakawa M, Toita T, Kakinohana Y, Kudaka W, Inamine M, Ariga T, Aoki Y, and Murayama S
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma radiotherapy, Adenocarcinoma surgery, Adult, Aged, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell radiotherapy, Carcinoma, Squamous Cell surgery, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Hysterectomy, Lymph Nodes surgery, Lymphatic Metastasis, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local radiotherapy, Neoplasm Recurrence, Local surgery, Neoplasm Staging, Pelvic Neoplasms radiotherapy, Pelvic Neoplasms secondary, Pelvic Neoplasms surgery, Postoperative Period, Prognosis, Retrospective Studies, Survival Rate, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms radiotherapy, Uterine Cervical Neoplasms surgery, Young Adult, Adenocarcinoma mortality, Carcinoma, Squamous Cell mortality, Lymph Nodes pathology, Neoplasm Recurrence, Local mortality, Pelvic Neoplasms mortality, Uterine Cervical Neoplasms mortality
- Abstract
Aim: To retrospectively analyze the treatment results of postoperative radiotherapy (PORT) in patients with early-stage uterine cervical cancer., Patients and Methods: Records of 141 patients with stage IB-IIB uterine cervical cancer treated with PORT from 1985 to 2004 were retrospectively reviewed. The majority of patients received whole-pelvic radiotherapy with antero-posterior fields, and the total radiation doses ranged from 10.8-60 Gy (median: 50.4 Gy). The median follow-up of all 141 patients was 106 months (range: 0.8-273.7 months)., Results: Multivariate analysis revealed that positive lymph node status (p=0.001) and histological type (p=0.015) were independent prognostic factors for overall survival. The group with three or more involved lymph nodes was significantly more likely to have extra-pelvic recurrence when compared with the groups with no (p=0.006) and up to two lymph nodes (p=0.024), respectively., Conclusion: PORT yielded excellent pelvic control rates for early-stage uterine cervical cancer. Lymph node status and histological type were significant prognostic factors for overall survival of patients with these tumors.
- Published
- 2013
60. Radical radiotherapy for superficial esophageal cancer: impact of clinical N stage on survival.
- Author
-
Ariga T, Ogawa K, Shimoji H, Karimata H, Toita T, Kakinohana Y, Kasuya G, Nishimaki T, Yoshimi N, and Murayama S
- Subjects
- Aged, Aged, 80 and over, Esophageal Neoplasms pathology, Female, Humans, Lymphatic Metastasis, Male, Middle Aged, Retrospective Studies, Survival Analysis, Esophageal Neoplasms radiotherapy
- Abstract
Aim: To retrospectively analyze the results of radical radiotherapy for patients with superficial esophageal cancer (SEC)., Patients and Methods: Forty-eight patients with SEC were reviewed. The median dose of external beam radiotherapy was 66 Gy (range, 30 to 70 Gy). Intraluminal brachytherapy was used in 10 patients, and 15 patients (31%) underwent chemotherapy. The median follow-up period was 28 months (range, 4 to 116 months)., Results: Sixteen patients had recurrence (11 patients: in-field local recurrence; 3 patients: regional lymph node recurrence; 2 patients: distant metastasis), and the 5-year local control (LC) rate was 74.2%. The 5-year overall survival and disease-free survival (DFS) rates were 44.5% and 48.6%, respectively. Patients with clinical N1 disease (5-year DFS: 0%) had significantly poorer DFS than patients with clinical N0 disease (5-year DFS: 51%, p=0.019)., Conclusion: Radical radiotherapy yielded relatively favorable LC rates in patients with SEC, and clinical N stage was a significant prognostic factor for DFS.
- Published
- 2012
61. Severe late complications in patients with uterine cancer treated with postoperative radiotherapy.
- Author
-
Kasuya G, Ogawa K, Iraha S, Nagai Y, Shiraishi M, Hirakawa M, Samura H, Toita T, Kakinohana Y, Kudaka W, Inamine M, Ariga T, Nishimaki T, Aoki Y, and Murayama S
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Multivariate Analysis, Prognosis, Uterine Neoplasms radiotherapy, Young Adult, Edema etiology, Enterocolitis etiology, Leg pathology, Postoperative Care, Radiotherapy adverse effects, Uterine Neoplasms complications, Uterine Neoplasms surgery
- Abstract
Aim: Severe late complications, particularly radiation enterocolitis and leg edema, remain major problems in patients with uterine cancer, who have undergone hysterectomy and postoperative external beam radiotherapy (EBRT). We carried out this retrospective analysis to identify the incidence of risk factors for such complications., Patients and Methods: The records of 228 patients, who underwent radical hysterectomy and postoperative EBRT (uterine cervix: 149 patients; uterine corpus: 79 patients) were reviewed retrospectively. The majority of the patients (90.8%) were treated with 50 to 50.4 Gy EBRT in conventional fractionations with anteroposterior fields. Intracavitary brachytherapy (ICBT) was administered to 9 patients (3.9%), and 35 patients (15.2%) received chemotherapy. The median follow-up for all 228 patients was 81.7 months (range, 1-273 months)., Results: Nineteen patients (8.3%) developed severe radiation enterocolitis with a median latency of 12.6 months, and the ileum was the most frequently affected site. On multivariate analysis, smoking was an independent predictor of severe radiation enterocolitis. Nineteen patients (8.3%) developed severe leg edema with a median latency of 32.7 months. The degree of leg edema did not improve in any of the 19 patients despite intensive treatment. On multivariate analysis, addition of ICBT was an independent predictor of severe leg edema., Conclusion: Severe radiation enterocolitis and severe leg edema were each observed in approximately 8% of patients with uterine cancer, who underwent postoperative radiotherapy. Severe radiation enterocolitis correlated strongly with smoking, and severe leg edema correlated strongly with addition of ICBT. These factors should be considered before administering postoperative radiotherapy to uterine cancer patients.
- Published
- 2011
62. Development of gastro-lymphatic fistula during chemoradiotherapy for advanced esophageal cancer: a case report.
- Author
-
Kasuya G, Ogawa K, Shimoji H, Tamaki W, Karimata H, Toita T, Kakinohana Y, Ariga T, Nishimaki T, and Murayama S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Esophageal Neoplasms drug therapy, Esophageal Neoplasms radiotherapy, Fatal Outcome, Fluorouracil administration & dosage, Gastric Fistula surgery, Humans, Lymphatic Diseases surgery, Male, Middle Aged, Organoplatinum Compounds administration & dosage, Esophageal Neoplasms pathology, Esophageal Neoplasms therapy, Gastric Fistula etiology, Lymphatic Diseases etiology
- Abstract
This is a case report of a gastro-lymphatic fistula which appeared during chemoradiotherapy for advanced esophageal cancer. A 60-year-old male was referred to the University of the Ryukyus Hospital because of a 10 kg monthly weight loss and dysphagia. Computed tomography (CT) scans indicated thickened esophageal wall at the lower thoracic esophagus and a swollen lymph node attached to the lesser curvature of the stomach. Histological analysis of the biopsy specimen revealed poorly differentiated squamous cell carcinoma and the diagnosis was of advanced esophageal cancer. A combination of chemotherapy (nedaplatin and 5-fluorouracil) and radiotherapy was initiated. After radiotherapy (20 Gy), CT scans revealed that the swollen lymph node penetrated the gastric wall resulting in a gastro-lymphatic fistula. Although gastrostomy and intestinal fistula repair were performed for gastric decompression and tube feeding, respectively, the patient's general status did not improve and he died two months after interruption of his chemoradiotherapy. The results indicate that there may be some risks of gastro-lymphatic fistula in patients treated with concurrent chemoradiotherapy for advanced esophageal cancer when there are possible signs of involvement by CT scans.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.